Contrasting Cullinan Oncology (NASDAQ:CGEM) & Aptose Biosciences (NASDAQ:APTO)
Contrasting Cullinan Oncology (NASDAQ:CGEM) & Aptose Biosciences (NASDAQ:APTO)
Cullinan Oncology (NASDAQ:CGEM – Get Rating) and Aptose Biosciences (NASDAQ:APTO – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.
庫利南腫瘤(納斯達克：CGEM-GET評級)和阿普託斯生物科學(納斯達克：APTO-GET評級)都是小盤醫療公司，但哪一家更好？我們將根據這兩家公司的風險、估值、股息、機構所有權、分析師建議、收益和盈利能力的強弱對它們進行比較。
Earnings & Valuation
收益與估值
This table compares Cullinan Oncology and Aptose Biosciences' revenue, earnings per share and valuation.
該表格比較了庫利南腫瘤學公司和Aptose生物科學公司的收入、每股收益和估值。
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cullinan Oncology | $18.94 million | 29.52 | -$65.57 million | $2.22 | 5.52 |
| Aptose Biosciences | N/A | N/A | -$65.35 million | ($0.61) | -1.09 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 庫利南腫瘤學 | 1894萬美元 | 29.52 | -6,557萬美元 | $2.22 | 5.52 |
| 阿普託斯生物科學 | 不適用 | 不適用 | -6,535萬元 | ($0.61) | -1.09 |
Aptose Biosciences has lower revenue, but higher earnings than Cullinan Oncology. Aptose Biosciences is trading at a lower price-to-earnings ratio than Cullinan Oncology, indicating that it is currently the more affordable of the two stocks.
Aptose Biosciences的收入低於Cullinan Oncology，但收益高於Cullinan Oncology。Aptose Biosciences的市盈率低於Cullinan Oncology，這表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
| Net Margins | Return on Equity | Return on Assets | |
| Cullinan Oncology | N/A | -33.66% | -31.74% |
| Aptose Biosciences | N/A | -92.87% | -81.08% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 庫利南腫瘤學 | 不適用 | -33.66% | -31.74% |
| 阿普託斯生物科學 | 不適用 | -92.87% | -81.08% |
Risk & Volatility
風險與波動性
Cullinan Oncology has a beta of -0.09, suggesting that its stock price is 109% less volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
庫利南腫瘤學的貝塔係數為-0.09，這表明其股價的波動性比標準普爾500指數低109%。相比之下，Aptose Biosciences的貝塔係數為1.39，這表明其股價的波動性比標準普爾500指數高39%。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and target prices for Cullinan Oncology and Aptose Biosciences, as provided by MarketBeat.
這是由MarketBeat提供的庫利南腫瘤學和Aptose生物科學公司最近的評級和目標價格細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cullinan Oncology | 0 | 0 | 3 | 0 | 3.00 |
| Aptose Biosciences | 0 | 0 | 4 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 庫利南腫瘤學 | 0 | 0 | 3 | 0 | 3.00 |
| 阿普託斯生物科學 | 0 | 0 | 4 | 0 | 3.00 |
Cullinan Oncology presently has a consensus target price of $50.00, indicating a potential upside of 307.83%. Aptose Biosciences has a consensus target price of $7.75, indicating a potential upside of 1,062.09%. Given Aptose Biosciences' higher probable upside, analysts clearly believe Aptose Biosciences is more favorable than Cullinan Oncology.
庫利南腫瘤學目前的共識目標價為50美元，表明潛在上漲307.83%。Aptose Biosciences的共識目標價為7.75美元，表明潛在漲幅為1,062.09%。考慮到Aptose Biosciences更有可能的上行空間，分析師們顯然認為Aptose Biosciences比Cullinan Oncology更有利。
Institutional & Insider Ownership
機構與內部人持股
82.5% of Cullinan Oncology shares are held by institutional investors. Comparatively, 27.2% of Aptose Biosciences shares are held by institutional investors. 7.5% of Cullinan Oncology shares are held by company insiders. Comparatively, 10.9% of Aptose Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
庫利南腫瘤學82.5%的股份由機構投資者持有。相比之下，Aptose Biosciences 27.2%的股份由機構投資者持有。庫利南腫瘤學7.5%的股份由公司內部人士持有。相比之下，Aptose Biosciences 10.9%的股份由公司內部人士持有。強大的機構持股表明，大型基金管理公司、對衝基金和捐贈基金相信，一家公司有望實現長期增長。
Summary
摘要
Cullinan Oncology beats Aptose Biosciences on 6 of the 11 factors compared between the two stocks.
在兩隻股票之間的11個因素中，庫利南腫瘤學在6個因素上擊敗了Aptose Bioscions。
About Cullinan Oncology
關於庫利南腫瘤學
(Get Rating)
(獲取評級)
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
庫利南腫瘤公司是一家生物製藥公司，專注於為美國的癌症患者開發一系列靶向腫瘤和免疫腫瘤療法。該公司的主要候選藥物是CLN-081，這是一種口服小分子藥物，正在進行I/IIa期劑量升級和擴大試驗，用於治療非小細胞肺癌患者。其臨牀前產品包括用於治療急性髓細胞白血病的人源化雙特異性抗體CLN-049；用於治療實體腫瘤的單抗CLN-619；用於治療實體腫瘤的融合蛋白CLN-617；用於治療B細胞惡性腫瘤的T細胞結合抗體CLN-978；用於阻斷PD-1軸並激活腫瘤T細胞上的4-IBB/CD137通路的雙特異性融合蛋白Opal；以及靶向衰老和癌症相關蛋白的細胞療法JADE。該公司與庫利南珍珠公司有合作協議，開發、製造和商業化CLN-081和含有CLN-081的產品；以及Adimab，LLC，以發現和/或優化抗體。庫利南腫瘤公司成立於2016年，總部設在馬薩諸塞州劍橋市。
About Aptose Biosciences
關於Aptose生物科學
(Get Rating)
(獲取評級)
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.
Aptose Biosciences Inc.是一家臨牀階段的生物技術公司，該公司發現和開發個性化療法，以滿足加拿大腫瘤學方面未得到滿足的醫療需求。它的主要臨牀計劃是APTO-253，這是一項治療復發或難治性血液系統惡性腫瘤患者的I期臨牀試驗。該公司已與CrystalGenology公司達成協議，研究、開發CG026806，並將其商業化。CG026806是一種非共價小分子治療劑，處於臨牀前階段，用於治療急性髓細胞白血病和慢性淋巴細胞白血病/套細胞淋巴瘤。該公司前身為Lorus治療公司，並於2014年8月更名為Aptose Biosciences Inc.。Aptose Biosciences Inc.成立於1986年，總部設在加拿大密西索加。
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
接受庫利南腫瘤學日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對庫利南腫瘤學和相關公司的最新新聞和分析師評級的每日簡明摘要。